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Nuclear medicine oers several techniques and procedures to image infection, but radiolabelled autologous white blood cells
(WBCs) are still the gold standard.ese cells are usually labelled with 111In or 99mTc bound to a hydrophobic chelating agent that
allows these isotopes to pass through the plasma membrane and enter in the cytoplasm.e most common compound in Europe
is HMPAO that eciently chelates 99mTc. However, up to 20–40% of the complex is released from the cells in the rst few hours.
e aim of this study was to radiolabel a new compound, (S3CPh)2 (S2CPh)-complex (SSS-complex) with 99mTc and compare its
binding kinetics and specicity for WBC with HMPAO.e SSS-complex was labelled with 99mTc and analysed by iTLC and RP-
HPLC. In vitro quality controls included a stability assay in serum and saline. Results showed a labelling eciency of 95 ± 1.2% and
98 ± 1.4% for 99mTc-SSS-complex and 99mTc-HMPAO, respectively (p  ns). 99mTc-SSS-complex was stable in serum and in saline
up to 24 h (94 ± 0.1%). Cell labelling experiments showed a higher incorporation of 99mTc-SSS-complex than 99mTc-HMPAO by
granulocytes (62.6 ± 17.8% vs 40.5 ± 15%, p  0.05), lymphocytes (59.9 ± 22.2% vs 29.4 ± 13.5%; p  0.03), and platelets (44.4 ±
24% vs 20.5 ± 10.7%; p  ns), but the release of radiopharmaceutical from granulocytes at 1 h was lower for HMPAO than for SSS-
complex (10.3 ± 1.9% vs 21.3 ± 1.8%; p  0.001). In conclusion, 99mTc-SSS-complex, although showing high labelling eciency,
radiochemical purity, and stability, is not a valid alternative to 99mTc-HMPAO, for example, in vivo white blood cells labelling
because of high lymphocyte and platelet uptake and rapid washout from granulocytes.
1. Introduction
e early and accurate localization of infectious foci and
inammation is a major challenge in contemporary nuclear
medicine. In 1970s, a method for imaging of
infections/inammation, based on the ex vivo labelling of
autologous leukocytes with Indium-111 (111In), was de-
veloped by akur and colleagues [1–3]. However, 111In
showed some drawbacks like poor image quality, unfavor-
able dosimetry, and cell toxicity, in particular on the white
blood cell (WBC) subsets [4–6].
erefore, newmethodologies were developed to replace
111In with 99mTc for ex vivo cell labelling, and in 1986, 99mTc-
HMPAO entered in clinical practice for WBC radiolabelling
and imaging of occult sites of infection [7]. 99mTc-HMPAO
is less toxic than 111In-oxine to WBC, providing a better
image quality and isotope availability. However, if not
completely reduced intracellularly, it may be released from
cells with time, especially in those patients with impaired
redox metabolism (hypovitaminosis, stress, metabolic dis-
eases, drugs, etc.).
Other several agents were tested as an alternative to
HMPAO to label WBC. In 90s, ethyl cysteinate dimer (ECD)
and d,l-cyclobutylpropylene amine oxime (d,l-CBPAO)
were labelled with 99mTc, and their labelling eciency and
stability were compared with 99mTc-HMPAO. Both showed
higher radiochemical purity than 99mTc-HMPAO, but only
99mTc-d,l-CBPAO provided a comparable binding to WBC.
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Despite being reported as a valid alternative to 99mTc-
HMPAO, it did not ﬁnd its place in clinical practice
[8, 9]. Pasqualini et al. in 2002 patented [99mTc
(S3CPh)2(S2CPh)] (SSS-complex) as a new radiopharma-
ceutical product for selective labelling of WBC, and in 2003,
Mevellec et al. published its synthesis using diﬀerent
methods [10, 11]. %ey demonstrated that the most eﬃcient
labelling method was based on the reaction of a lyophilized
formulation of 99mTc-gluconate with the sodium salt of
phenyldithiocarboxylic acid. However, no systematic studies
have ever been published to show the binding kinetics and
speciﬁcity of this complex.
%erefore, in the present study, we performed the
radiolabelling with 99mtechnetium of SSS-complex and
tested its radiochemical purity, stability, binding speciﬁcity,
and kinetics to diﬀerent blood cell subsets as compared to
99mTc-HMPAO.
2. Materials and Methods
2.1. Radiolabelling of SSS-Complex. A technetium-99m re-
ducing kit, containing 4mg of thin chloride dihydrate, 30mg
of sodium gluconate, 40mg of potassium oxalate, and 30mg
of ascorbic acid, was reconstituted with 10ml of saline
solution, and 1ml of this solution was added to freshly eluted
99mTcO4− (370–720MBq).%emixture was gently stirred for
10min at room temperature, and then, 8–10mg of SSS-
complex in 1ml of saline solution was added. After 15min of
incubation at 100°C, labelling eﬃciency (LE) and colloid
percentages were measured.
2.2. In Vitro Quality Controls. Quality controls were per-
formed using both instant thin layer chromatography
(iTLC) and reversed phase-HPLC (RP-HPLC). For iTLC,
silica-gel strips were used as stationary phase (Pall Life
Sciences, Port Washington, NY), whereas a 0.5M
ethanol/toluene/chloroform/ammonium acetate 6 : 3 : 3 : 1
solution was used asmobile phase. In these conditions, it was
possible to diﬀerentiate pertechnetate (Rf � 0.5) and the
intermediate gluconate complex (Rf � 0). A mixture of
petroleum ether and dichloromethane (6 : 4) was used as the
mobile phase to perform quality controls of the 99mTc-SSS-
complex (Rf � 0.7). %e strips were analyzed by a radio-
scanner (Bioscan, Inc, Poway, CA) to calculate the LE. %e
complex was also analyzed by RP-HPLC using a C18 column
(5mm, 5 μm, 250× 4.6mm, Phenomenex, Torrance, CA)
and the following mobile phase: H2O and THF gradient
(0–3min 70% H2O; 3–17min 100% THF; 17–30min 70%
H2O) with a ﬂow rate of 1ml/min.
Stability assays were performed adding 100 μl of 99mTc-
SSS-complex to 900 μl of fresh human blood serum or to
900 μl of 0.9% saline solution. %e vials were incubated up to
24 h at 37°C. %e LE was measured at 1, 3, 6, and 24 h by
iTLC [12].
2.3. Radiolabelling of White Blood Cells with 99mTc-SSS-
Complex. To evaluate SSS-complex speciﬁcity for WBC,
whole blood from 4 healthy volunteers (40ml) was collected
and mixed with anticoagulant citrate dextrose ACD (8ml).
%e blood was stratiﬁed in a centrifuge tube containing 20ml
of lympholyte® (Cedarlane).%e vial was centrifuged at 500 g
for 20min at room temperature. After centrifugation,
platelets, mononuclear cells (MNCs), red blood cells (RBC),
and polymorphonuclear cells (PMNCs) were separated as
described in the guidelines [13, 14]. Purity of each cell
population was determined by FACS analysis. Platelets,
MNCs, and PMNCs (16×106 cells) were separately collected
and incubated with 99mTc-SSS-complex (74MBq) under
gentle stirring for 10min at 37°C. Free 99mTc-SSS-complex
was removed by centrifugation at 600 g for 10min and
washing with PBS. Cell-bound and free radioactivity was
determined by counting the pellet and the supernatant,
respectively. %e labelling yield was calculated as 100∗MBq
pellet/MBq pellet + MBq supernatants. 99mTc-HMPAO-
WBC were prepared as described by EANM guidelines
and used as control [13].
2.4. Stability Assay. Stability of labelled cells was assessed
incubating granulocytes, lymphocytes, and platelets in PBS
at 37°C. After 1 h and 3 h, an aliquot from each vial was
centrifuged to collect pellet and supernatant that were
counted for radioactivity with a single-well gamma counter
(Atomlab 500, Biodex) in order to evaluate the radiophar-
maceutical elution from labelled cells over time.
%e trypan blue exclusion test was also performed in
order to verify the viability of each cell population at dif-
ferent time points after labelling.
3. Results
3.1. Labelling of SSS-Complex. %e labelling eﬃciency of
99mTc-SSS-complex was >95%, as assessed by both iTLC and
RP-HPLC analysis (Figure 1). In particular, the area below
the curve of free 99mTc is 1.8% at iTLC and 4.2% at HPLC.
%e resulting labelled complex was highly stable in both
human serum and saline up to 24 h (94 ± 0.1%) (Figure 2).
3.2. Cell Separation and Labelling Technique. FACS analysis
revealed a good separation of each blood cell subset, with
a purity of >90%. A statistically signiﬁcant higher accu-
mulation of 99mTc-SSS-complex was observed in each
subpopulation as compared to 99mTc-HMPAO after cell
labelling (Figure 3). 99mTc-SSS-complex did not show se-
lectivity for any particular blood cell subset as well as 99mTc-
HMPAO. In particular, granulocytes were labelled with 62.6± 17.8% eﬃciency with 99mTc-SSS-complex and 40.5 ± 15%
eﬃciency with 99mTc-HMPAO (p � 0.05); lymphocytes were
labelled with 59.9 ± 22.2% eﬃciency with 99mTc-SSS-
complex and 29.4 ± 13.5% eﬃciency with 99mTc-HMPAO
(p � 0.03); ﬁnally, platelets were labelled with 44.4 ± 24%
eﬃciency with 99mTc-SSS-complex and 20.5 ± 10.7% eﬃ-
ciency with 99mTc-HMPAO (p � ns).
Regarding 99mTc-SSS-complex, retention experiments
showed a rapid decrease of radioactivity in each cell pop-
ulation after 1 h (21.3 ± 1.8%, 40.9 ± 19.6%, and 58.1 ± 33.3%,
respectively, for granulocytes, lymphocytes, and platelets),
with a further washout up to 3 h (38.6 ± 13.8%, 75.8 ± 10.5%,
and 87.6 ± 10.1%, respectively, for granulocytes, lymphocytes,
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and platelets). 99mTc-HMPAO shows a slower washout from
each cells subset at each time point (Figure 4). Particularly,
99mTc-HMPAO showed the following values of washout:
10.3 ± 1.9% (p � 0.001), 41.6 ± 18.5%, and 63.3 ± 9.1%,
respectively, for granulocytes, lymphocytes, and platelets at
1 h, and 18.9 ± 1.6% (p � 0.05), 42.2 ± 15.4% (p � 0.005), and
67.4 ± 6.8% (p � 0.003) at 3 h for granulocytes, lymphocytes,
and platelets, respectively.
Labelling of cell subsets with 99mTc-SSS-complex showed
no cell toxicity, with more than 99 ± 0.4% viable cells after
24 h.
4. Discussion
%e development of radiopharmaceuticals to distinguish
sterile inﬂammation from infection is still an open challenge,
and it is crucial for the diagnosis of various bone and soft
tissue diseases, including osteomyelitis, diabetic foot, im-
mune bowel diseases (IBD), and fever of unknown origin
(FUO) too. According to international standardized
guidelines, 99mTc-HMPAO-WBC or 111In-oxine-WBC are
the gold standard to image infection because of their high
speciﬁcity and rapid clearance from lungs and blood [13, 14].
%ey speciﬁcally accumulate in infectious foci where a neu-
trophilic inﬁltrate predominates as a result of migration
through the endothelium and basalmembrane [15–17].When
using 111In-oxine or 99mTc-HMPAO for WBC labelling,
a portion of lymphocytes are also radiolabelled. Since lym-
phocytes are very sensitive to radiation damage [18], it would
be ideal to have a Tc-chelating agent that will selectively label
only granulocytes in a mixed WBC suspension.
%erefore, the aim of our study was to investigate the
properties of a novel compound for granulocyte labelling:
the SSS-complex. %is was radiolabelled with 99mTc and
compared with HMPAO. %e labelling procedure of SSS-
complex showed a >95% LE with negligible amount of
99mTc-colloids and high stability in both human serum and
0.9% NaCl solution.
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Figure 1: iTLC (a) and HPLC (b) of the radiolabelled compound. Measuring the area under the curve of each peak, the labelling eﬃciency of
99mTc-SSS-complex is 98.2% as calculated by iTLC and 95.8% as calculated by HPLC. %e two peaks (free 99mTc and 99mTc-SSS) at ra-
diochromatogram in b are wider than the UV peaks because the volume of the UV cell is only 10 µl and the volume of radiochromatogram
cell is 50 µl for sensitivity reasons.
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When compared to 99mTc-HMPAO for WBC labelling,
we found a higher labelling eciency of 99mTc-SSS-complex
with respect to 99mTc-HMPAO for granulocyte, lymphocyte,
and platelet labelling (Figure 3). But washout from these cells
was much faster than 99mTc-HMPAO in all cell populations,
reaching 38.6±13.8% of washout from granulocytes at 3 h
(Figure 4).
Indeed, granulocytes labelled with 99mTc-HMPAO
showed a retention of radioactivity of 90% at 1 h and of
80% at 3 h versus only 80% and 61%, respectively, when la-
belled with 99mTc-SSS-complex. Washout from lymphocytes
and platelets was similar at 1 h between the two radiophar-
maceuticals, but higher for 99mTc-SSS-complex at 3 h in both
cell subsets.
Based on these results, it appears that 99mTc-SSS-
complex cannot substitute 99mTc-HMPAO for selective la-
belling of granulocytes. It enters into all cell subsets, and
most importantly, it is ejected from granulocytes in a higher
percentage than 99mTc-HMPAO. is behavior may aect
image quality in vivo.
In an attempt to nd a better agent for WBC labelling,
Capriotti et al. compared 99mTc-HMPAO and 99mTc-
stannous colloids in 2004 [19]. In this study, 99mTc-
HMPAO showed a lower and signicant spontaneous ra-
dioactivity release at dierent time points in all subjects
studied, conrming it as the best choice to label WBC.
WBCs were also labelled with 99mTc-liposomes [20] and
with 99mTc-P483H [21]. Radiolabelled liposomes showed
a minimum release after washings at 2 and 6 h, while 99mTc-
P483H showed a radioactivity associated with WBC equal to
76.5%, both obtaining better results than 99mTc-SSS-complex
but similar to those achievable with 99mTc-HMPAO.
Since there are no other Tc-chelating agents available for
WBC labelling, the only alternative consists in the use of
antigranulocyte antibodies [22–24], leaving open doors to
the study of new radiopharmaceuticals for bacterial imaging,
although radiopharmaceuticals synthetized until now
showed several limitations [25, 26].
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Figure 2: Stability of radiolabelled 99mTc-SSS-complex in saline
(diamonds) and in human serum (circles) over time.
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Granulocytes Lymphocytes Platelets
Time 0
1h
3h
%
 w
as
ho
ut
∗∗
∗∗
0
50
100
∗
∗∗∗
(a)
Time 0
1h
3h
%
 w
as
ho
ut
Granulocytes Lymphocytes Platelets
0
50
100
(b)
Figure 4: Washout of 99mTc-SSS-complex and 99mTc-HMPAO in
dierent labelled cell populations. All values are normalized to
activity at t  0 (black bars) and evaluated at 1 h (grey bars) and 3 h
(white bars), expressed as mean ± SD of four to seven experiments.
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5. Conclusion
99mTc-SSS-complex, although labels white blood cells with
high eﬃciency, showed no selectivity for any particular cell
subset, and as the main limiting factor, it showed a high
spontaneous release from granulocytes over time. %erefore,
in conclusion, 99mTc-SSS-complex cannot be considered as
a valid alternative to 99mTc-HMPAO to label granulocytes
for in vivo use as an infection seeking agent.
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